Not sure... I have always thought Painchek is trying to balance between a patient centric healthcare company vs a for profit hype micro-cap company. It has certainly leaned towards the former at the detriment of abysmal TSR for the past 2.5 years.
That said though.. I don't like the 4C update on assessments # vs the presentation.. the 4C commentary stipulated a much higher assessments done in the quarter vs what is shown on the investor presentation.. it's either misleading on intention or unprofessional in its proof reading.
Not sure... I have always thought Painchek is trying to balance...
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
